Shopping for long-term care.

D. Stone

DOI: https://doi.org/10.1377/HLTHAFF.23.4.191

2004-07-01

Health Affairs

Abstract:

What problem does this paper attempt to address?

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

Sheng-an Su,Du Yang,Yue Wu,Yao Xie,Wei Zhu,Zhejun Cai,Jian Shen,Zurong Fu,Yaping Wang,Liangliang Jia,Yidong Wang,Jian-an Wang,Meixiang Xiang

DOI: https://doi.org/10.1161/circresaha.117.311045

IF: 23.213

2017-01-01

Circulation Research

Abstract:Rationale: Cardiac fibrosis is a common feature in left ventricular remodeling that leads to heart failure, regardless of the cause. EphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression. Recently, EphrinB2 was reported to protect kidneys from injury-induced fibrogenesis. However, its role in cardiac fibrosis remains to be clarified.Objective: We sought to determine the role of EphrinB2 in cardiac fibrosis and the underlying mechanisms during the pathological remodeling process.Methods and Results: EphrinB2 was highly expressed in the myocardium of patients with advanced heart failure, as well as in mouse models of myocardial infarction and cardiac hypertrophy induced by angiotensin II infusion, which was accompanied by myofibroblast activation and collagen fiber deposition. In contrast, intramyocardial injection of lentiviruses carrying EphrinB2-shRNA ameliorated cardiac fibrosis and improved cardiac function in mouse model of myocardial infarction. Furthermore, in vitro studies in cultured cardiac fibroblasts demonstrated that EphrinB2 promoted the differentiation of cardiac fibroblasts into myofibroblasts in normoxic and hypoxic conditions. Mechanistically, the profibrotic effect of EphrinB2 on cardiac fibroblast was determined via activating the Stat3 (signal transducer and activator of transcription 3) and TGF-beta (transforming growth factor-beta)/Smad3 (mothers against decapentaplegic homolog 3) signaling. We further determined that EphrinB2 modulated the interaction between Stat3 and Smad3 and identified that the MAD homology 2 domain of Smad3 and the coil-coil domain and DNA-binding domain of Stat3 mediated the interaction.Conclusions: This study uncovered a previously unrecognized profibrotic role of EphrinB2 in cardiac fibrosis, which is achieved through the interaction of Stat3 with TGF-beta/Smad3 signaling, implying a promising therapeutic target in fibrotic diseases and heart failure.
MRTF: Basic Biology and Role in Kidney Disease

Maria Zena Miranda,Zsuzsanna Lichner,Katalin Szászi,András Kapus

DOI: https://doi.org/10.3390/ijms22116040

IF: 5.6

2021-06-03

International Journal of Molecular Sciences

Abstract:A lesser known but crucially important downstream effect of Rho family GTPases is the regulation of gene expression. This major role is mediated via the cytoskeleton, the organization of which dictates the nucleocytoplasmic shuttling of a set of transcription factors. Central among these is myocardin-related transcription factor (MRTF), which upon actin polymerization translocates to the nucleus and binds to its cognate partner, serum response factor (SRF). The MRTF/SRF complex then drives a large cohort of genes involved in cytoskeleton remodeling, contractility, extracellular matrix organization and many other processes. Accordingly, MRTF, activated by a variety of mechanical and chemical stimuli, affects a plethora of functions with physiological and pathological relevance. These include cell motility, development, metabolism and thus metastasis formation, inflammatory responses and—predominantly-organ fibrosis. The aim of this review is twofold: to provide an up-to-date summary about the basic biology and regulation of this versatile transcriptional coactivator; and to highlight its principal involvement in the pathobiology of kidney disease. Acting through both direct transcriptional and epigenetic mechanisms, MRTF plays a key (yet not fully appreciated) role in the induction of a profibrotic epithelial phenotype (PEP) as well as in fibroblast-myofibroblast transition, prime pathomechanisms in chronic kidney disease and renal fibrosis.

biochemistry & molecular biology,chemistry, multidisciplinary
Mice Overexpressing Latent Tgf-Beta 1 Are Protected Against Renal Fibrosis In Obstructive Kidney Disease

Xiao R. Huang,Arthur C. K. Chung,Xiao J. Wang,Kar Neng Lai,Hui Y. Lan

DOI: https://doi.org/10.1152/ajprenal.00021.2008

2008-01-01

American Journal of Physiology - Renal Physiology

Abstract:Transforming growth factor (TGF)-beta 1, once activated, binds to its receptors and mediates renal fibrosis via the downstream Smad signaling pathway. We reported here that mice overexpressing latent TGF-beta 1 in keratinocytes were protected against renal fibrosis in a model of obstructive kidney disease. In normal mice, both transgenic (Tg) and wild-type (WT) mice had normal renal histology and function, despite a 10-fold increase in plasma latent TGF-beta 1 in Tg mice. A severe renal fibrosis was developed in WT mice at 7 days after urinary obstruction. Unexpectedly, renal fibrosis was prevented in Tg mice, although levels of latent TGF-beta 1 in both circulation and renal tissues remained high. Compared with the WT mice, quantitative real-time PCR showed that upregulation of renal alpha-smooth muscle actin (SMA), collagen I, and collagen III mRNA was inhibited in Tg mice (60 -70% reduced, all P < 0.01). These were further confirmed by immunohistochemistry with a marked inhibition of tubulointerstitial accumulation of alpha-SMA + fibroblasts, collagen I, and collagen III matrix in Tg mice (all P < 0.001). Further studies showed that inhibition of renal fibrosis in Tg mice was associated with a significant reduction in renal TGF-beta 1 and CTGF (60% reduced, P < 0.05), an increase in renal Smad7, a suppression of TSP-1 (a critical factor for TGF-beta 1 activation), and an inhibition of Smad2/ 3 activation (all P < 0.001). In conclusion, latent TGF-beta may play a protective role in renal fibrosis. Inhibition of renal TGF-beta 1 expression and activation, thereby blocking the downstream TGF-beta signaling pathway, may be a critical mechanism by which latent TGF-beta 1 protects against renal fibrosis.
'De novo' absence status of late onset

P. Thomas,A. Beaumanoir,P. Genton,C. Dolisi,M. Chatel

DOI: https://doi.org/10.1212/WNL.42.1.104

IF: 9.9

1992-01-01

Neurology

Abstract:Absence status (AS) is a heterogenous epileptic syndrome that can occur at any age, usually in a context of prior epilepsy. Eleven cases of AS occurring in middle-aged patients who had no history of epilepsy were retrospectively collected over a 10-year period (10 women and one man; mean age, 58.6 years). Eight patients were receiving high doses of psychotropic drugs. Clinical and EEG presentation was similar to AS occurring in patients with prior epilepsy. Evaluation of precipitating factors revealed that AS coincided with benzodiazepine withdrawal in eight cases. Cofactors included excessive use of other psychotropic drugs, nonpsychotropic treatment, hypocalcemia, hyponatremia, and chronic alcoholism. CT demonstrated mild cerebral atrophy in six cases. There was no recurrence, even without chronic antiepileptic treatment. These data indicate that (1) most cases of “de novo” AS of middle age or late onset result from the addition of various epileptogenic factors; (2) AS can be considered a new and uncommon complication of benzodiazepine withdrawal, and (3) long-term administration of anticonvulsant medication may not be required.
Epiregulin (EREG) and Myocardin Related Transcription Factor A (MRTF-A) Form a Feedforward Loop to Drive Hepatic Stellate Cell Activation

Xiaoyan Wu,Wenhui Dong,Tianyi Zhang,Haozhen Ren,Jinglin Wang,Longcheng Shang,Zhengyi Zhu,Wei Zhu,Xiaolei Shi,Yong Xu

DOI: https://doi.org/10.3389/fcell.2020.591246

IF: 5.5

2021-01-01

Frontiers in Cell and Developmental Biology

Abstract:Trans-differentiation of quiescent hepatic stellate cells (HSC) into myofibroblast cells is considered the linchpin of liver fibrosis. A myriad of signaling pathways contribute to HSC activation and consequently liver fibrosis. Epidermal growth factor (EGF) family of cytokines signal through the cognate receptor EGFR to promote HSC activation. In the present study we investigated the transcription regulation of epiregulin (EREG), an EGFR ligand, during HSC activation. We report that EREG expression was significantly up-regulated in activated HSCs compared to quiescent HSCs isolated from mice. In addition, there was an elevation of EREG expression in HSCs undergoing activation in vitro. Of interest, deficiency of myocardin-related transcription factor A (MRTF-A), a well-documented regulator of HSC trans-differentiation, attenuated up-regulation of EREG expression both in vivo and in vitro. Further analysis revealed that MRTF-A interacted with serum response factor (SRF) to bind directly to the EREG promoter and activate EREG transcription. EREG treatment promoted HSC activation in vitro, which was blocked by MRTF-A depletion or inhibition. Mechanistically, EREG stimulated nuclear trans-location of MRTF-A in HSCs. Together, our data portray an EREG-MRTF-A feedforward loop that contributes to HSC activation and suggest that targeting the EREG-MRTF-A axis may yield therapeutic solutions against liver fibrosis.
Modulation of transforming growth factor-β-induced kidney fibrosis by leucine-rich ⍺-2 glycoprotein-1

Quan Hong,Hong Cai,Lu Zhang,Zhengzhe Li,Fang Zhong,Zhaohui Ni,Guangyan Cai,Xiang-Mei Chen,John Cijiang He,Kyung Lee

DOI: https://doi.org/10.1016/j.kint.2021.10.023

IF: 19.6

2022-02-01

Kidney International

Abstract:Kidney fibrosis is considered the final convergent pathway for progressive chronic kidney diseases, but there is still a paucity of success in clinical application for effective therapy. We recently demonstrated that the expression of secreted leucine-rich α-2 glycoprotein-1 (LRG1) is associated with worsened kidney outcomes in patients with type 2 diabetes and that LRG1 enhances endothelial transforming growth factor-β signaling to promote diabetic kidney disease progression. While the increased expression of LRG1 was most prominent in the glomerular endothelial cells in diabetic kidneys, its increase was also observed in the tubulointerstitial compartment. Here, we explored the potential role of LRG1 in kidney epithelial cells and TGF-β-mediated tubulointerstitial fibrosis independent of diabetes. LRG1 expression was induced by tumor necrosis factor-α in cultured kidney epithelial cells and potentiated TGF-β/Smad3 signal transduction. Global Lrg1 loss in mice led to marked attenuation of tubulointerstitial fibrosis in models of unilateral ureteral obstruction and aristolochic acid fibrosis associated with concomitant decreases in Smad3 phosphorylation in tubule epithelial cells. In mice with kidney epithelial cell-specific LRG1 overexpression, while no significant phenotypes were observed at baseline, marked exacerbation of tubulointerstitial fibrosis was observed in the obstructed kidneys. This was associated with enhanced Smad3 phosphorylation in both kidney epithelial cells and α-smooth muscle actin-positive interstitial cells. Co-culture of kidney epithelial cells with primary kidney fibroblasts confirmed the potentiation of TGF-β-mediated Smad3 activation in kidney fibroblasts through epithelial-derived LRG1. Thus, our results indicate that enhanced LRG1 expression-induced epithelial injury is an amplifier of TGF-β signaling in autocrine and paracrine manners promoting tubulointerstitial fibrosis. Hence, therapeutic targeting of LRG1 may be an effective means to curtail kidney fibrosis progression in chronic kidney disease.

urology & nephrology
Cardiac chamber volumes, function, and mass as determined by 64-multidetector row computed tomography: mean values among healthy adults free of hypertension and obesity.

F. Lin,R. Devereux,M. Roman,Joyce Meng,Veronica M Jow,Avrum Jacobs,J. Weinsaft,L. Shaw,D. Berman,T. Callister,J. Min

DOI: https://doi.org/10.1016/j.jcmg.2008.04.015

IF: 16.051

2008-11-01

JACC Cardiovascular Imaging

Abstract:
Egr-1 mediates chronic hypoxia-induced renal interstitial fibrosis via the PKC/ERK pathway

Shiren Sun,Xiaoxuan Ning,Ying Zhai,Rui Du,Yuanyuan Lu,Lijie He,Rong Li,Weini Wu,Wenjuan Sun,Hanmin Wang

DOI: https://doi.org/10.1159/000362249

Abstract:Background: Chronic hypoxia-induced epithelial-to-mesenchymal transition (EMT) is a crucial process in renal fibrogenesis. Egr-1, as a transcription factor, has been proven to be important in promoting EMT. However, whether it functions in hypoxia-induced renal tubular EMT has not been fully elucidated. Methods: Egr-1 were detected at mRNA and protein levels by qPCR and Western blot analysis respectively after renal epithelial cells were subjected to hypoxia treatment. Meanwhile, EMT phenotype was also observed through identification of relevant EMT-specific markers. siRNA was used to knock down Egr-1 expression and subsequent changes were observed. Specific PKC and MAPK/ERK inhibitors were employed to determine the molecular signaling pathway involved in Egr-1-mediated EMT phenotype. In vivo assays using rat remnant kidney model were used to validate the in vitro results. Furthermore, Egr-1 expression was examined in the samples of CKD patients with the clinical relevance revealed. Results: Hypoxia treatment enhanced the mRNA and protein levels of Egr-1 in HK-2 cells, which was accompanied by a reduced expression of the epithelial marker E-cadherin and an enhanced expression of the mesenchymal marker Fsp-1. Downregulation of Egr-1 with siRNA reversed hypoxia-induced EMT. Using the specific inhibitors to protein kinase C (calphostin C) or MAPK/ERK (PD98059), we identified that hypoxia induced Egr-1 expression through the PKC/ERK pathway. In addition, the upregulation of Egr-1 raised endogenous Snail levels, and the downregulation of Snail inhibited Egr-1-mediated EMT in HK-2 cells. Through in vivo assays using rat remnant kidney and CKD patients' kidney tissues, we found that Egr-1 and Snail were overexpressed in tubular epithelial cells with EMT. Conclusion: Egr-1 may be an important regulator of the development of renal tubular EMT induced by hypoxia through the PKC/ERK pathway and the activation of Snail. Targeting Egr-1 expression or activity might be a novel therapeutic strategy to control renal fibrosis.
EGR1 interacts with p-SMAD at the endothelin-1 gene promoter to regulate gene expression in TGFβ1-stimulated IMR-90 fibroblasts

Tae Yoon Kim,Hyunjin Yeo,Euitaek Jung,Soon Young Shin

DOI: https://doi.org/10.1016/j.bbrc.2024.150567

2024-08-20

Abstract:Pulmonary fibrosis is a severe and progressive lung disease characterized by lung tissue scarring. Transforming growth factor beta 1 (TGFβ1) is crucial in causing pulmonary fibrosis by promoting the activation of fibroblasts and their differentiation into myofibroblasts, which are responsible for excessive extracellular matrix deposition. This study aimed to identify genes activated by TGFβ1 that promote fibrosis and to understand the regulatory pathway controlling myofibroblast. Endothelin-1 (ET-1) was identified as the top-ranking gene in the fibrosis-related gene set using quantitative PCR array analysis. TGFβ1 upregulated EGR1 expression through the ERK1/2 and JNK1/2 MAPK pathways. EGR1 and p-SMAD2 proteins interacted with the ET-1 gene promoter region to regulate TGFβ1-induced ET-1 expression in IMR-90 pulmonary fibroblasts. Mice lacking the Egr1 gene showed reduced ET-1 levels in a model of pulmonary fibrosis induced by intratracheal administration of bleomycin. These findings suggest that targeting EGR1 is a promising approach for treating pulmonary fibrosis, especially idiopathic pulmonary fibrosis, by affecting ET-1 expression and profibrotic reactions.
Critical role for the TGF-β1/mTORC1 signalling axis in defining the transcriptional identity of CTHRC1+ pathologic fibroblasts

Jo-Anne A M Wilson,Rachel Walters,Delphine Guillotin,Naftali Kaminski,Silvia Parolo,Manuela Platé,Rachel C Chambers

DOI: https://doi.org/10.1101/2024.10.12.617979

2024-10-14

Abstract:Fibrosis, defined as the abnormal deposition of extracellular matrix (ECM), represents the concluding pathological outcome in a number of inflammatory, immune-mediated and metabolic diseases. Recent single cell RNA-sequencing studies have highlighted the diversity and functional heterogeneity of fibroblast populations in multiple fibrotic conditions. These include a novel pathogenic population of high collagen-producing fibroblasts, characterised by expression of the secreted glycoprotein, collagen triple helix repeat containing 1 (CTHRC1). The cardinal pro-fibrotic mediator TGF-β1 has been widely implicated in promoting fibrogenesis and is a potent inducer of CTHRC1 and COL1A1 expression. In addition to the canonical Smad signalling pathway, TGF-β1-induced collagen I production is under critical regulatory control by the mTORC1/4E-BP1 signalling hub. Using pharmacological inhibition in combination with gene-editing approaches, we now demonstrate that the role of the mTORC1 axis extends to the regulation of over a third of all TGF-β1 regulated matrisome genes. We provide further evidence that the global transcriptome of TGF-β1-stimulated fibroblasts in vitro matches that of a subpopulation of the high collagen expressing CTHRC1+ pathological fibroblast population in the IPF lung. In contrast, the TGF-β1 induced transcriptome of fibroblasts in which mTORC1 signalling is disrupted (by RPTOR gene editing using CRISPR-Cas9) does not map to any fibroblast population present in human control or fibrotic lung. Using the novel and selective mTORC1 inhibitor RMC-5552, we further demonstrate a direct functional link between mTORC1 signalling and the acquisition of key marker genes which define the CTHRC1+ fibroblast population in IPF. These data demonstrate, for the first time, a critical role for the mTORC1 signalling hub in determining the transcriptional identity of the CTHRC1+ pathological fibroblast population and provide strong scientific support for targeting mTORC1 as a therapeutic strategy in IPF and potentially other fibrotic conditions associated with dysregulated TGF-β1 signalling in the fibrotic niche.

Cell Biology
Inhibition of MRTF-A Ameliorates Pathological Remodeling of the Pressure-loaded Right Ventricle

Mark F Rzepka,Sonja Raschzok,Xavier A Lee,Kana Yazaki,John Dauz,Mei Sun,Theo Meister,Linda Nghiem,Golam Kabir,Jean-Francois Desjardins,Wolfgang M Kuebler,Andras Kapus,Kim A Connelly,Mark K Friedberg

DOI: https://doi.org/10.1165/rcmb.2023-0465OC

2024-08-20

Abstract:Right ventricular (RV) fibrosis is associated with RV dysfunction in a variety of RV pressure-loading conditions where RV mechanical stress is increased, but the underlying mechanisms driving RV fibrosis are incompletely understood. In pulmonary and cardiovascular diseases characterized by elevated mechanical stress and transforming growth factor - beta-1 (TGF-β1) signaling, myocardin-related transcription factor A (MRTF-A) is a mechanosensitive protein critical to driving myofibroblast transition and fibrosis. Here we investigated whether MRTF-A inhibition improves RV pro-fibrotic remodeling and function in response to a pulmonary artery banding (PAB) model of RV pressure-loading. Rats were assigned into either 1) sham or 2) PAB groups. MRTF-A inhibitor CCG-1423 was administered daily at 0.75mg/kg in a subset of PAB animals. Echocardiography and pressure-volume hemodynamics were obtained at a terminal experiment 6-weeks later. RV myocardial samples were analyzed for fibrosis, cardiomyocyte hypertrophy, and pro-fibrotic signaling. MRTF-A inhibition slightly reduced systolic dysfunction in PAB rats reflected by increased lateral tricuspid annulus peak systolic velocity, while diastolic function parameters were not significantly improved. RV remodeling was attenuated in PAB rats with MRTF-A inhibition, displaying reduced fibrosis. This was accompanied with a reduction in PAB-induced upregulation of yes-associated protein (YAP) and its paralog transcriptional co-activator with PDZ-binding motif (TAZ). We also confirmed using a second-generation MRTF-A inhibitor CCG-203971 that MRTF-A is critical in driving RV fibroblast expression of TAZ and markers of myofibroblast transition in response to TGF-β1 stress and RhoA activation. These studies identify RhoA, MRTF-A, and YAP/TAZ as interconnected regulators of pro-fibrotic signaling in RV pressure-loading, and as potential targets to improve RV pro-fibrotic remodeling.
Fibroblast Nrf2 inhibits profibrotic transcription with Ddx54 and mitigates pathological fibrosis in the mouse heart and kidney

Atsushi Hoshino,Toshiyuki Nishiji,Nariko Ikemura,Mellissa C Alcantara,Yusuke Higuchi,Yuki Uchio,Yuhei Kirita,Shunta Taminishi,Yuki Ozaki,Daisuke Motooka,Ryosuke Kobayashi,Takuro Horii,Izuho Hatada,Satoaki Matoba

DOI: https://doi.org/10.1101/2023.11.09.566496

2023-11-11

bioRxiv

Abstract:Background: Tissue fibrosis is a common feature of many organ dysfunctions, such as heart failure and chronic kidney disease. However, no fundamental treatment has been developed. This study aims to identify novel molecular mechanisms for antifibrotic intervention, focusing on fibroblast activation. Methods: We performed a forward genetic screen using a genome-wide CRISPR library in the context of transforming growth factor ? (TGF-?)-mediated connective tissue growth factor (CTGF) expression, and used unbiased techniques such as Cleavage Under Targets and Tagmentation (CUT&Tag) and proximity-dependent biotin labeling by TurboID to reveal the detailed molecular mechanisms. Results: CRISPR library screening identified a number of players in both the canonical Smad pathway and the non-canonical pathway. In addition to the known factors, the Keap1-Nrf2 pathway was identified as a predominant regulator of TGF-?-mediated CTGF expression. Keap1 deletion and consequent Nrf2 activation broadly suppressed profibrotic gene expression, independently of conventional antioxidant effects. CUT&Tag revealed that Nrf2 bound to the proximity of fibrosis-related genes including Ctgf and Fn1. Subsequent individual analysis revealed Smad3 and RNA polymerase II binding to the Nrf2 peak site, which was attenuated by Keap1 deletion. TurboID experiments further discovered that Nrf2 interacts with Ddx54, which acts as a corepressor. Consistently, Keap1 deletion-mediated repression of profibrotic gene expression was reversed by additional Ddx54 deletion. The impact of the Keap1-Nrf2 pathway on pathological fibrosis was examined using tamoxifen-inducible fibroblast-specific Keap1 knockout mice. Pressure overload for 4 weeks robustly induced cardiac hypertrophy, fibrosis and contractile dysfunction. However, deletion of Keap1 in the Postn lineage attenuated these cardiac pathologies. The anti-fibrotic effects of Keap1 deletion were also confirmed in renal fibrosis in the unilateral ureteral obstruction (UUO) model. Conclusions: Fibroblast Nrf2 transcriptionally represses fibrosis-related genes in cooperation with the corepressor Ddx54. Fibroblast-specific deletion of Keap1 attenuated pathological fibrosis in pressure overload heart failure and renal fibrosis.
Rac-GTPase promotes fibrotic TGF-β1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways

Samik Patel,Jiaqi Tang,Jessica M Overstreet,Sandybell Anorga,Fei Lian,Alex Arnouk,Roel Goldschmeding,Paul J Higgins,Rohan Samarakoon

DOI: https://doi.org/10.1096/fj.201802489RR

Abstract:Rac-GTPases are major regulators of cytoskeletal remodeling and their deregulation contributes to numerous pathologies. Whether or how Rac promotes tubulointerstitial fibrosis and chronic kidney disease (CKD) is currently unknown. We showed that the major profibrotic cytokine, TGF-β1 promoted rapid Rac1-GTP loading in human kidney 2 (HK-2) human renal epithelial cells. A Rac-specific chemical inhibitor, EHT 1864, blocked TGF-β1-induced fibrotic reprogramming in kidney epithelial cells and fibroblasts. Stable Rac1 depletion in HK-2 cells, moreover, eliminated TGF-β1-mediated non-SMAD pathway activation [e.g., Src, epidermal growth factor receptor (EGFR), p53] and subsequent plasminogen activator inhibitor-1 (PAI-1), connective tissue growth factor, fibronectin, and p21 induction. Rac1 and p22phox knockdown abrogated free radical generation by TGF-β1 in HK-2 cells, consistent with the role of Rac1 in NAPD(H). TGF-β1-induced renal epithelial cytostasis was also completely bypassed by Rac1, p22phox, p47phox, and PAI-1 silencing. Rac1b isoform expression was robustly induced in the fibrotic kidneys of mice and humans. Intraperitoneal administration of EHT 1864 in mice dramatically attenuated ureteral unilateral obstruction-driven EGFR, p53, Rac1b, yes-associated protein/transcriptional coactivator with PDZ-binding motif activation/expression, dedifferentiation, cell cycle arrest, and renal fibrogenesis evident in vehicle-treated obstructed kidneys. Thus, the Rac1-directed redox response is critical for TGF-β1-driven epithelial dysfunction orchestrated, in part, via PAI-1 up-regulation. Rac pathway inhibition suppressed renal oxidative stress and maladaptive repair, identifying Rac as a novel therapeutic target against progressive CKD.-Patel, S., Tang, J., Overstreet, J. M., Anorga, S., Lian, F., Arnouk, A., Goldschmeding, R., Higgins, P. J., Samarakoon, R. Rac-GTPase promotes fibrotic TGF-β1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways.
Regulation of cardiac fibrosis in mice with TAC/DOCA‐induced HFpEF by resistin‐like molecule gamma and adenylate cyclase 1

Dawei Liu,Fanling Zeng,Zhiyu Chen,Zheng Qin,Zhiqiang Liu

DOI: https://doi.org/10.1002/2211-5463.13813

2024-05-07

FEBS Open Bio

Abstract:A mouse model of heart failure with preserved ejection fraction (HFpEF) was established to explore key fibrosis‐related genes and pathways in the HFpEF pathophysiological process. Potential candidate genes were identified by bioinformatic analyses and further validated in vivo. Our results suggest that Relmg and Acdy1 as well as the fibrosis process may be potential targets for HFpEF treatment. Heart failure with preserved ejection fraction (HFpEF) is one of the major subtypes of heart failure (HF) and no effective treatments for this common disease exist to date. Cardiac fibrosis is central to the pathology of HF and a potential avenue for the treatment of HFpEF. To explore key fibrosis‐related genes and pathways in the pathophysiological process of HFpEF, a mouse model of HFpEF was constructed. The relevant gene expression profiles were downloaded from the Gene Expression Omnibus database, and single‐sample Gene Set Enrichment Analysis (ssGSEA) was performed targeting fibrosis‐related pathways to explore differentially expressed genes (DEGs) in healthy control and HFpEF heart tissues with cross‐tabulation analysis of fibrosis‐related genes. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the identified fibrosis‐related genes. The two most significant DEGs were selected, and further validation was conducted in HFpEF mice. The results indicated that myocardial fibrosis was significantly upregulated in HFpEF mice compared to healthy controls, while the ssGSEA results revealed significant differences in the enrichment of nine fibrosis‐related pathways in HFpEF myocardial tissue, with 112 out of 798 DEGs being related to fibrosis. The in vivo results demonstrated that expression levels of resistin‐like molecule gamma (Relmg) and adenylate cyclase 1 (Adcy1) in the heart tissues of HFpEF mice were significantly higher and lower, respectively, compared to healthy controls. Taken together, these results suggest that Relmg and Acdy1 as well as the fibrosis process may be potential targets for HFpEF treatment.

biochemistry & molecular biology
Myocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in Polycystic Kidney Disease

Zsuzsanna Lichner,Mei Ding,Tarang Khare,Qinghong Dan,Raquel Benitez,Mercédesz Praszner,Xuewen Song,Rola Saleeb,Boris Hinz,York Pei,Katalin Szászi,András Kapus

DOI: https://doi.org/10.3390/cells13110984

IF: 6

2024-06-05

Cells

Abstract:Polycystic kidney disease (PKD) is characterized by extensive cyst formation and progressive fibrosis. However, the molecular mechanisms whereby the loss/loss-of-function of Polycystin 1 or 2 (PC1/2) provokes fibrosis are largely unknown. The small GTPase RhoA has been recently implicated in cystogenesis, and we identified the RhoA/cytoskeleton/myocardin-related transcription factor (MRTF) pathway as an emerging mediator of epithelium-induced fibrogenesis. Therefore, we hypothesized that MRTF is activated by PC1/2 loss and plays a critical role in the fibrogenic reprogramming of the epithelium. The loss of PC1 or PC2, induced by siRNA in vitro, activated RhoA and caused cytoskeletal remodeling and robust nuclear MRTF translocation and overexpression. These phenomena were also manifested in PKD1 (RC/RC) and PKD2 (WS25/−) mice, with MRTF translocation and overexpression occurring predominantly in dilated tubules and the cyst-lining epithelium, respectively. In epithelial cells, a large cohort of PC1/PC2 downregulation-induced genes was MRTF-dependent, including cytoskeletal, integrin-related, and matricellular/fibrogenic proteins. Epithelial MRTF was necessary for the paracrine priming of the fibroblast–myofibroblast transition. Thus, MRTF acts as a prime inducer of epithelial fibrogenesis in PKD. We propose that RhoA is a common upstream inducer of both histological hallmarks of PKD: cystogenesis and fibrosis.

cell biology
Selective Activation of Epidermal Growth Factor Receptor in Renal Proximal Tubule Induces Tubulointerstitial Fibrosis.

Jessica M Overstreet,Yinqiu Wang,Xin Wang,Aolei Niu,Leslie S Gewin,Bing Yao,Raymond C Harris,Ming-Zhi Zhang

DOI: https://doi.org/10.1096/fj.201601359rr

2017-01-01

Abstract:Epidermal growth factor receptor (EGFR) has been implicated in the pathogenesis of diabetic nephropathy and renal fibrosis; however, the causative role of sustained EGFR activation is unclear. Here, we generated a novel kidney fibrotic mouse model of persistent EGFR activation by selectively expressing the EGFR ligand, human heparin‐binding EGF‐like growth factor (hHB‐EGF), in renal proximal tubule epithelium. hHB‐EGF expression increased tyrosine kinase phosphorylation of EGFR and the subsequent activation of downstream signaling pathways, including ERK and AKT, as well as the profibrotic TGF‐β1/SMAD pathway. Epithelial‐specific activation of EGFR was sufficient to promote spontaneous and progressive renal tubulointerstitial fibrosis, as characterized by increased collagen deposition, immune cell infiltration, and α‐smooth muscle actin (α‐SMA)–positive myofibroblasts. Tubule‐specific EGFR activation promoted epithelial dedifferentiation and cell‐cycle arrest. Furthermore, EGFR activation in epithelial cells promoted the proliferation of α‐SMA+ myofibroblasts in a paracrine manner. Genetic or pharmacologic inhibition of EGFR tyrosine kinase activity or downstream MEK activity attenuated the fibrotic phenotype. This study provides definitive evidence that sustained activation of EGFR in proximal epithelia is sufficient to cause spontaneous, progressive renal tubulointerstitial fibrosis, evident by epithelial dedifferentiation, increased myofibroblasts, immune cell infiltration, and increased matrix deposition.—Overstreet, J. M., Wang, Y., Wang, X., Niu, A., Gewin, L. S., Yao, B., Harris, R. C., Zhang, M.‐Z. Selective activation of epidermal growth factor receptor in renal proximal tubule induces tubulointerstitial fibrosis. FASEB J. 31,4407‐4421 (2017). www.fasebj.org
Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation.

Min Yang,Haichang Huang,Jingzi Li,Dongxia Li,Haiyan Wang

DOI: https://doi.org/10.1096/fj.04-2357fje

2004-01-01

Abstract:Renal myofibroblasts play a crucial role in the accumulation of excess extracellular matrix during renal fibrosis. Both transforming growth factor-beta1 (TGFbeta1) and connective tissue growth factor (CTGF) are important profibrotic growth factors, which interact in the pathogenesis of fibrosis. In this study, we demonstrate that CTGF alone has no influence on myofibroblast transformation and fibronectin secretion in kidney interstitial fibroblasts, whereas incubation of CTGF in combination with TGFbeta1 enhanced TGFbeta1 responses, including myofibroblast activation, de novo expression of alpha-SMA, and extracellular accumulation of fibronectin. CTGF induced tryrosine phosphorylation of the cytoplasmic domain of the low-density lipoprotein receptor-associated protein (LRP) in fibroblasts, and the LRP-antagonist, receptor-associated protein (RAP) inhibited CTGF-induced tryrosine phosphorylation of LRP. Inhibition of LRP signaling reduced CTGF-mediated synergistic induction of alpha-SMA protein. Furthermore, the potentiating action of CTGF was neither dependent on modulation of TGFbeta1-induced Smad2 phosphorylation and its association with Smad4, nor did it result from nuclear accumulation of activated Smad2. When TGFbeta1-pretreated fibroblasts were incubated with CTGF, activation of ERK1/2 MAPK signaling was observed. Inhibition of ERK activation by the MEK1 inhibitor PD98059 was associated with a reduction of CTGF-promoted alpha-SMA protein expression. Our in vitro studies provide evidence that CTGF potentiates TGFbeta1-mediated myofibroblast differentiation and activates differentiated myofibroblasts.
Myocardin-related transcription factor drives epithelial fibrogenesis in polycystic kidney disease

Zsuzsanna Lichner,Mei Ding,Tarang Khare,Qinghong Dan,Raquel Benitez,Mercédesz Praszner,Xuewen Song,Rola Saleeb,Boris Hinz,York Pei,Katalin Szászi,András Kapus

DOI: https://doi.org/10.1101/2024.03.15.585204

2024-03-17

Abstract:Polycystic kidney disease (PKD) is characterized by extensive cyst formation and progressive fibrosis. However, the molecular mechanisms whereby the loss/loss-of-function of Polycystin 1 or 2 (PC1/2) provokes fibrosis are largely unknown. The small GTPase RhoA has been recently implicated in , and we have shown that the RhoA/cytoskeleton/myocardin-related transcription factor (MRTF) pathway is a key mediator of epithelium-induced fibrogenesis. Therefore, we hypothesized that MRTF is activated by PC1/2 loss and plays a critical role in fibrogenic reprogramming of the epithelium. Loss of PC1 or PC2 induced by siRNA in vitro activated RhoA, caused cytoskeletal remodeling and robust nuclear MRTF translocation and overexpression. These phenomena were also manifest in PKD1 (RC/RC) and PKD2 (WS25/-) mice, with MRTF translocation and overexpression occurring predominantly in dilated tubules and in cyst-lining epithelium, respectively. In epithelial cells, a large cohort of PC1/PC2 downregulation-induced genes was MRTF-dependent, including cytoskeletal, integrin-related, and matricellular/fibrogenic proteins. Epithelial MRTF was necessary for paracrine priming of fibroblast-myofibroblast transition. Thus, MRTF is a critical novel mediator of the PC1/2 loss-induced profibrotic epithelial phenotype, and consequently PKD-related fibrosis.

Cell Biology
Regulation of extracellular matrix gene expression and biosynthetic pathways in pulmonary fibroblasts by HSF1

Mikayla Jones,Christina TK Wales,Rachel A Gristock,Aaron T Jacobs

DOI: https://doi.org/10.1096/fasebj.31.1_supplement.lb490

2017-04-01

The FASEB Journal

Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic and rapidly progressing lung disease that is characterized by extensive tissue remodeling, impaired gas exchange, and a poor prognosis. The pathogenesis of IPF involves epithelial cell death, leukocyte infiltration and cytokine production, enhanced deposition of collagen and remodeling of the extracellular matrix (ECM). One key event in the progression of IPF is the activation of fibroblasts that is mediated by TGF‐beta, which leads to tissue remodeling. We have investigated a possible role for the transcription factor, heat shock factor 1 (HSF1) in the expression of pro‐fibrotic genes in TGF‐beta treated fibroblasts. siRNA was used to silence the expression of HSF1 in pulmonary fibroblast cell lines, MRC‐5 and IMR‐90. Cells were treated with TGF‐beta for 0, 8, and 24 h, after which RNA and protein samples were collected. RNA samples were analyzed by real‐time PCR to assess differences in the expression of several target genes with known roles in the production and remodeling of ECM, and results were verified by Western blot. Silencing HSF1 altered the expression of several ECM‐related genes in both cell lines, indicting role for HSF1 in the control of ECM biogenesis and remodeling by TGF‐beta stimulated fibroblasts, and a possible significance for HSF1 activity in the etiology of IPF. In addition to components of fibrillar collagen (COL1A1, COL1A2), the expression of several genes that function in the biogenesis of collagen fibers also were impaired by HSF1 silencing, including proteins with proline hydroxylase (P4HA2), lysyl hydroxylase (PLOD1), prolyl isomerase (FKBP4); and chaperone activities (SERPINE1, SERPINH1). In contrast to its effects on fibrillar collagen biogenesis, HSF1 silencing enhanced the expression of genes involved in elastic fibers production, including: elastin (ELN) microfibrillar‐associated protein 4 (MFAP4); and fibulin 5 (FBLN5). This observation is consistent with the finding by others that the ratio of collagen and elastin fibers is altered in IPF, further indicating a unique role for HSF1 in controlling the composition of the ECM in this disease. Support or Funding Information Funding provided by the Leahi Fund of the Hawaii Community Foundation

cell biology,biochemistry & molecular biology,biology
Epidermal growth factor receptor activation is essential for kidney fibrosis development

Shirong Cao,Yu Pan,Andrew S. Terker,Juan Pablo Arroyo Ornelas,Yinqiu Wang,Jiaqi Tang,Aolei Niu,Sarah Abu Kar,Mengdi Jiang,Wentian Luo,Xinyu Dong,Xiaofeng Fan,Suwan Wang,Matthew H. Wilson,Agnes Fogo,Ming-Zhi Zhang,Raymond C. Harris

DOI: https://doi.org/10.1038/s41467-023-43226-x

IF: 16.6

2023-11-14

Nature Communications

Abstract:Abstract Fibrosis is the progressive accumulation of excess extracellular matrix and can cause organ failure. Fibrosis can affect nearly every organ including kidney and there is no specific treatment currently. Although Epidermal Growth Factor Receptor (EGFR) signaling pathway has been implicated in development of kidney fibrosis, underlying mechanisms by which EGFR itself mediates kidney fibrosis have not been elucidated. We find that EGFR expression increases in interstitial myofibroblasts in human and mouse fibrotic kidneys. Selective EGFR deletion in the fibroblast/pericyte population inhibits interstitial fibrosis in response to unilateral ureteral obstruction, ischemia or nephrotoxins. In vivo and in vitro studies and single-nucleus RNA sequencing analysis demonstrate that EGFR activation does not induce myofibroblast transformation but is necessary for the initial pericyte/fibroblast migration and proliferation prior to subsequent myofibroblast transformation by TGF-ß or other profibrotic factors. These findings may also provide insight into development of fibrosis in other organs and in other conditions.

multidisciplinary sciences

Shopping for long-term care.

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

MRTF: Basic Biology and Role in Kidney Disease

Mice Overexpressing Latent Tgf-Beta 1 Are Protected Against Renal Fibrosis In Obstructive Kidney Disease

'De novo' absence status of late onset

Epiregulin (EREG) and Myocardin Related Transcription Factor A (MRTF-A) Form a Feedforward Loop to Drive Hepatic Stellate Cell Activation

Modulation of transforming growth factor-β-induced kidney fibrosis by leucine-rich ⍺-2 glycoprotein-1

Cardiac chamber volumes, function, and mass as determined by 64-multidetector row computed tomography: mean values among healthy adults free of hypertension and obesity.

Egr-1 mediates chronic hypoxia-induced renal interstitial fibrosis via the PKC/ERK pathway

EGR1 interacts with p-SMAD at the endothelin-1 gene promoter to regulate gene expression in TGFβ1-stimulated IMR-90 fibroblasts

Critical role for the TGF-β1/mTORC1 signalling axis in defining the transcriptional identity of CTHRC1+ pathologic fibroblasts

Inhibition of MRTF-A Ameliorates Pathological Remodeling of the Pressure-loaded Right Ventricle

Fibroblast Nrf2 inhibits profibrotic transcription with Ddx54 and mitigates pathological fibrosis in the mouse heart and kidney

Rac-GTPase promotes fibrotic TGF-β1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways

Regulation of cardiac fibrosis in mice with TAC/DOCA‐induced HFpEF by resistin‐like molecule gamma and adenylate cyclase 1

Myocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in Polycystic Kidney Disease

Selective Activation of Epidermal Growth Factor Receptor in Renal Proximal Tubule Induces Tubulointerstitial Fibrosis.

Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation.

Myocardin-related transcription factor drives epithelial fibrogenesis in polycystic kidney disease

Regulation of extracellular matrix gene expression and biosynthetic pathways in pulmonary fibroblasts by HSF1

Epidermal growth factor receptor activation is essential for kidney fibrosis development